PASSITUM-S is a Good Empirical choice

CEFOPERAZONE-SULBACTAM

• Active against a wide range of gram-positive
  and gram-negative bacteria including Pseudomonas, E. Coli and Klebsiella
• Sulbactam inhibits a wide range of betalactamases including ESBLs, thereby widening the antibacterial spectrum of the combination
• Synergy with aminoglycosides
• Safe in hepatic and renal impairment and no dosage adjustments required (except in combined and severe impairment)

PASSITUM - S IN SERIOUS HOSPITAL ACQUIRED INFECTIONS

• Achieves high peak serum concentrations
• Sulbactam lowers MIC values of
  Cefoperazone for B-lactamase producing
  and non-producing strains.
• Ensures high cure with dependable
  clinical efficacy and safety
• Overall side effects - 4%